Gold ticks up but remains pressured by Fed rate caution, easing trade fears
LONDON - Morgan Stanley & Co. International plc disclosed Wednesday that it purchased and sold 1,161 ordinary shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) on October 28, 2025, according to a regulatory filing with the Irish Takeover Panel.
The transactions were executed at prices ranging from $18.5611 to $18.5618 per share, as reported in the Form 38.5(a) filing under the Irish Takeover Panel Act rules.
Morgan Stanley is acting as an exempt principal trader with recognized intermediary status in a client-serving capacity in relation to Avadel Pharmaceuticals. The disclosure indicates that Morgan Stanley purchased and subsequently sold the same number of shares on the same day.
The filing, made in compliance with Rule 38.5(a) of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, confirms that Morgan Stanley has no indemnity arrangements, agreements, or understandings relating to options or derivatives regarding Avadel’s securities.
The disclosure is required as Morgan Stanley is connected to Avadel Pharmaceuticals in relation to an unspecified offer or potential transaction involving the company.
No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the filing.
The information was submitted to a Regulatory Information Service as required under Rule 38 of the Irish Takeover Rules, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.